دورية أكاديمية
Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy.
| العنوان: | Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy. |
|---|---|
| المؤلفون: | Magavern EF; Centre of Clinical Pharmacology and Precision Medicine, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, United Kingdom., Kapil V; Centre of Clinical Pharmacology and Precision Medicine, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, United Kingdom., Saxena M; Centre of Clinical Pharmacology and Precision Medicine, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, United Kingdom., Gupta A; Centre of Clinical Pharmacology and Precision Medicine, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, United Kingdom., Caulfield MJ; Centre of Clinical Pharmacology and Precision Medicine, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, United Kingdom. |
| المصدر: | Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] 2024 Apr; Vol. 44 (4), pp. 784-793. Date of Electronic Publication: 2024 Feb 22. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9505803 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1524-4636 (Electronic) Linking ISSN: 10795642 NLM ISO Abbreviation: Arterioscler Thromb Vasc Biol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1998- : Baltimore, Md. : Lippincott Williams & Wilkins Original Publication: Dallas, TX : American Heart Association, c1995- |
| مواضيع طبية MeSH: | Hypertension*/drug therapy , Hypertension*/genetics, Humans ; Blood Pressure/genetics ; Multifactorial Inheritance ; Genomics ; Pharmacogenetics |
| مستخلص: | Hypertension is a prevalent public health problem, contributing to >10 million deaths annually. Though multiple therapeutics exist, many patients suffer from treatment-resistant hypertension or try several medications before achieving blood pressure control. Genomic advances offer mechanistic understanding of blood pressure variability, therapeutic targets, therapeutic response, and promise a stratified approach to treatment of primary hypertension. Cyclic guanosine monophosphate augmentation, aldosterone synthase inhibitors, and angiotensinogen blockade with silencing RNA and antisense therapies are among the promising novel approaches. Pharmacogenomic studies have also been done to explore the genetic bases underpinning interindividual variability in response to existing therapeutics. A polygenic approach using risk scores is likely to be the next frontier in stratifying responses to existing therapeutics. Competing Interests: Disclosures None. |
| فهرسة مساهمة: | Keywords: genomics; hypertension; pharmacogenetics; pharmacology; therapeutics |
| تواريخ الأحداث: | Date Created: 20240222 Date Completed: 20240329 Latest Revision: 20240329 |
| رمز التحديث: | 20240329 |
| DOI: | 10.1161/ATVBAHA.123.319220 |
| PMID: | 38385287 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1524-4636 |
|---|---|
| DOI: | 10.1161/ATVBAHA.123.319220 |